相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists
M. L. Y. de Koning et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
The Global Burden of Disease Study and the Preventable Burden of NCD
Catherine P. Benziger et al.
GLOBAL HEART (2016)
Oral Antithrombotic Effects of Acylhydrazone Derivatives
Flvia Serra Frattani et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2013)
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation
A. Tripodi et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Antiplatelet therapy: thrombin receptor antagonists
Antonio Tello-Montoliu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs
Motoji Kogushi et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Arterial thrombus formation in cardiovascular disease
Giuseppe Lippi et al.
NATURE REVIEWS CARDIOLOGY (2011)
The Role of Platelets in Atherothrombosis
Zane S. Kaplan et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
Shinya Goto et al.
EUROPEAN HEART JOURNAL (2010)
Safety and Exploratory Efficacy of the Novel Thrombin Receptor (PAR-1) Antagonist SCH530348 for Non-ST-Segment Elevation Acute Coronary Syndrome
Shinya Goto et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2010)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
Gilles Montalescot et al.
LANCET (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
P2Y12 antagonism -: Promises and challenges
Alan D. Michelson
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott et al.
CIRCULATION (2008)
Synthesis and anti-platelet activity of novel arylsulfonate-acylhydrazone derivatives, designed as antithrombotic candidates
Lidia M. Lima et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2008)
Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity
Samuel Chackalamannil et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Triggers, targets and treatments for thrombosis
Nigel Mackman
NATURE (2008)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Beyond unfractionated heparin and warfarin - Current and future advances
Jack Hirsh et al.
CIRCULATION (2007)
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
BI Eriksson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Protease-activated receptors in hemostasis, thrombosis and vascular biology
SR Coughlin
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -: an oral, direct Factor Xa inhibitor
E Perzborn et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Antithrombotic effect of Glycyrrhizin, a plant-derived thrombin inhibitor
W Mendes-Silva et al.
THROMBOSIS RESEARCH (2003)
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent
JM Walenga et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
分享论文
